Top 10 drugs
Top 10 drugs 2025-26
- Aust Prescr 2026;49:255
- 1 December 2026
- DOI: 10.18773/austprescr.2026.057
Tables 1 to 3 show the top 10 drugs for the year 1 July 2025 to 30 June 2026. The figures are based on PBS and RPBS prescriptions from the date of supply.
Table 1 Top 10 PBS and RPBS drugs by DDD/1000 population/day
| Drug | DDD/1000 population/day |
|
1. rosuvastatin |
96.70 |
|
2. atorvastatin |
73.26 |
|
3. sertraline |
33.30 |
|
4. escitalopram |
30.36 |
|
5. pantoprazole |
29.80 |
|
6. perindopril |
28.15 |
|
7. candesartan |
26.45 |
|
8. denosumab |
24.39 |
|
9. levothyroxine |
23.37 |
|
10. ramipril |
22.99 |
Table 2 Top 10 PBS and RPBS drugs by prescription counts
| Drug | Prescriptions |
|
1. rosuvastatin |
16,713,299 |
|
2. pantoprazole |
11,112,856 |
|
3. atorvastatin |
10,861,917 |
|
4. esomeprazole |
7,677,309 |
|
5. escitalopram |
6,526,324 |
|
6. sertraline |
6,345,132 |
|
7. perindopril |
6,168,074 |
|
8. metformin |
6,099,200 |
|
9. cefalexin |
5,151,186 |
|
10. amoxicillin |
4,826,012 |
Table 3 Top 10 PBS and RPBS drugs by cost to government (does not include rebates)
| Drug | Cost to government | Prescriptions | Main indications |
|
1. pembrolizumab |
$664,648,568 |
79,051 |
cancer immunotherapy |
|
2. elexacaftor+tezacaftor+ivacaftor with ivacaftor |
$619,628,158 |
30,503 |
cystic fibrosis |
|
3. dupilumab |
$619,293,030 |
360,888 |
severe asthma, atopic eczema |
|
4. nivolumab |
$458,251,347 |
64,690 |
cancer immunotherapy |
|
5. semaglutide |
$395,871,168 |
3,248,779 |
type 2 diabetes, obesity |
|
6. aflibercept |
$361,469,701 |
482,685 |
age-related macular degeneration |
|
7. upadacitinib |
$360,273,174 |
246,474 |
atopic dermatitis, inflammatory arthritides |
|
8. daratumumab |
$310,953,655 |
44,260 |
multiple myeloma, light chain amyloidosis |
|
9. apixaban |
$305,948,100 |
4,681,549 |
prevention and treatment of thrombosis |
|
10. ocrelizumab |
$251,510,441 |
15,345 |
multiple sclerosis |
Australian Prescriber welcomes Feedback.